These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 27249709)

  • 1. Basic Overview of Current Immunotherapy Approaches in Cancer.
    Velcheti V; Schalper K
    Am Soc Clin Oncol Educ Book; 2016; 35():298-308. PubMed ID: 27249709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combinatorial immunotherapy and nanoparticle mediated hyperthermia.
    Moy AJ; Tunnell JW
    Adv Drug Deliv Rev; 2017 May; 114():175-183. PubMed ID: 28625829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combinatorial Cancer Immunotherapies.
    Hellmann MD; Friedman CF; Wolchok JD
    Adv Immunol; 2016; 130():251-77. PubMed ID: 26923003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers for Immunotherapy: Current Developments and Challenges.
    Spencer KR; Wang J; Silk AW; Ganesan S; Kaufman HL; Mehnert JM
    Am Soc Clin Oncol Educ Book; 2016; 35():e493-503. PubMed ID: 27249758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune Checkpoint Inhibitors: Basics and Challenges.
    Li B; Chan HL; Chen P
    Curr Med Chem; 2019; 26(17):3009-3025. PubMed ID: 28782469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Development of novel immunotherapy targeting cancer immune evasion].
    Tamada K
    Gan To Kagaku Ryoho; 2014 Sep; 41(9):1062-5. PubMed ID: 25248888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progress and opportunities for enhancing the delivery and efficacy of checkpoint inhibitors for cancer immunotherapy.
    Francis DM; Thomas SN
    Adv Drug Deliv Rev; 2017 May; 114():33-42. PubMed ID: 28455187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concluding Remarks.
    Xu J; Liu M
    Adv Exp Med Biol; 2020; 1248():651-653. PubMed ID: 32185727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetics and immunotherapy: The current state of play.
    Dunn J; Rao S
    Mol Immunol; 2017 Jul; 87():227-239. PubMed ID: 28511092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune checkpoint blockade in lymphoid malignancies.
    Thanarajasingam G; Thanarajasingam U; Ansell SM
    FEBS J; 2016 Jun; 283(12):2233-44. PubMed ID: 26807978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Milestone Survival: A Potential Intermediate Endpoint for Immune Checkpoint Inhibitors.
    Chen TT
    J Natl Cancer Inst; 2015 Sep; 107(9):. PubMed ID: 26113579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Introduction.
    Liu J; Xu J
    Adv Exp Med Biol; 2020; 1248():1-6. PubMed ID: 32185704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential biomarker for checkpoint blockade immunotherapy and treatment strategy.
    Dong ZY; Wu SP; Liao RQ; Huang SM; Wu YL
    Tumour Biol; 2016 Apr; 37(4):4251-61. PubMed ID: 26779629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune checkpoint signaling and cancer immunotherapy.
    He X; Xu C
    Cell Res; 2020 Aug; 30(8):660-669. PubMed ID: 32467592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Checkpoint Inhibitors: Applications for Autoimmunity.
    Tocheva AS; Mor A
    Curr Allergy Asthma Rep; 2017 Sep; 17(10):72. PubMed ID: 28956259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perspectives for immunotherapy in endocrine cancer.
    Latteyer S; Tiedje V; Schilling B; Führer D
    Endocr Relat Cancer; 2016 Oct; 23(10):R469-84. PubMed ID: 27485460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances in immunotherapies: from infection and autoimmunity, to cancer, and back again.
    Bucktrout SL; Bluestone JA; Ramsdell F
    Genome Med; 2018 Oct; 10(1):79. PubMed ID: 30376867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer immunotherapy by targeting immune checkpoints: mechanism of T cell dysfunction in cancer immunity and new therapeutic targets.
    Tsai HF; Hsu PN
    J Biomed Sci; 2017 May; 24(1):35. PubMed ID: 28545567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Tumour assessment criteria for immune checkpoint inhibitors].
    Wasielewski E; Cortot AB
    Rev Mal Respir; 2018 Oct; 35(8):828-845. PubMed ID: 30166076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade.
    Postow MA; Sidlow R; Hellmann MD
    N Engl J Med; 2018 Jan; 378(2):158-168. PubMed ID: 29320654
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 23.